

EHA-GBMTA-AHA Hematology Tutorial - New aspects in diagnostic choices and treatment options of hematological malignancies

Self-assessment case 1 Speaker: Kamila Polgárová, Prague, Czech Republic


Tbilisi, Georgia October 18-20, 2024



Introduction

- male, 63 years with history of hypertension and no other significant comorbidities
- History of colorectal carcinoma within parental family
- Presented with cervical and inguinal palpable and painless masses and subcutaneous nodular lesions
- fevers and night sweats appeared soon after masses were observed followed by rapid unintended weight loss
- Fine needle aspiration was indicated by general practitioner with inconclusive results
- Core-cut biopsy from cervical mass showed:

Immunohistochemistry



Q1) What is the diagnosis?

- 1. Diffuse large B-cell lymphoma
- 2. Follicular lymphoma
- 3. Anaplastic large cell lymphoma
- 4. Mantle cell lymphoma
- 5. Burkitt lymphoma
- 6. Small cell lymphoma


Q1) What is the diagnosis?

- 1. Diffuse large B-cell lymphoma
- 2. Follicular lymphoma
- 3. Anaplastic large cell lymphoma



- 5. Burkitt lymphoma
- 6. Small cell lymphoma

Staging and risk scoring



Clinical stage (Ann Arbor): IVB – generalized lymphadenopathy, liver, spleen and kidneys infiltration, bone marrow infiltration, intramuscular and subcutaneous nodules, CNS (leptomeningeal) involvement

- MIPI(c) score 9.1
 - Age: 63 yrs
 - LDH: 10.1 μkat/L (upper limit: 3.8 μkat/L)
 - WBC: 5.8x10⁹/L
 - ECOG 2
 - Ki67 100%

Q2) What is the prognosis?

- 1. Failure-free survival 5-8 months, OS 11-16 months
- 2. Failure-free survival 9-13 months, OS 24-30 months
- 3. Failure-free survival 36 months, OS 5 years
- 4. Failure-free survival 5 years, OS 10 years


Q2) What is the prognosis?

1. Failure-free survival 5-8 months, OS 11-16 months

2. Failure-free survival 9-13 months, OS 24-30 months

- 3. Failure-free survival 36 months, OS 5 years
- 4. Failure-free survival 5 years, OS 10 years

Survival of high-risk MCL



1183 MCL pts with Ann Arbor stage II-IV

+ validation cohorts

High risk: MIPIc high risk or p53 expression > 50%

High-risk x low risk:

- FFS 1.1 yrs x 5.6 yrs, HR 2.97, p < 0.0001
- OS 2.2 yrs x 13.2 yrs, HR 3.69, p < 0.0001
- Discriminatory power confirmed in subgroup analyses in elderly and younger MCL groups
- R-CHOP+R-DHAP vs. R-CHOP partially mitigates the dismal prognosis

Q3) What other factors define the prognosis?


- 1. TP53 and CDKN2A mutation
- 2. BCL2 and BCL6 expression
- 3. Superficial CD5 expression
- 4. IgG rearrangement
- 5. Response to corticoid pretreatment

Q3) What other factors define the prognosis?



- 2. BCL2 and BCL6 expression
- 3. Superficial CD5 expression
- 4. IgG rearrangement
- 5. Response to corticoid pretreatment

Factors defining prognosis of MCL patients



Malarikova D et al. Cancers 2020 Delfau-Larue MH et al. Blood 2015 Koff LJ et al. Blood 2022 suppl. Abstr. No 140


- CDKN2A aberrations are probably a late event (described exclusively in the context of other gene aberrations)
- **TP53 + CDKN2A aberrations** independent marker of chemoresistance
 - EFS 3 months; OS 10 months
 - Addition of HD AraC regimen does not mitigate the dismal prognosis
 - New modalities, intensified treatment and upfront HSCT should be considered

Other aberrations with negative impact:

- RB1 deletion
- CDKN1B deletion
- (ATM del, cMYC gain contradicting data)

Case report: prognostic factors and FISH and NGS findings

- Clinical stage: IVB
- MIPI(c) score 9.1
- Ki67 100%
- TP53 deletion ATM deletion
- RB1 deletion
- CDKN2A deletion



Time to treatment failure in patients from European MCL Younger trial treated by chemoimmunotherapy (R-CHOP (E) or R-CHOP/R-DHAP) followed by ASCT

Q4) What is the preferred first line treatment

- 1. R-CHOP
- 2. R-Bendamustin
- 3. R-DHAP + venetoclax
- 4. R-(maxi)CHOP alt. R-DHAP + ibrutinib
- 5. R-hyperCVAD alt. R-HD-MTX

Q4) What is the preferred first line treatment

- 1. R-CHOP
- 2. R-Bendamustin
- 3. R-DHAP + venetoclax

4. R-(maxi)CHOP alt. R-DHAP + ibrutinib


5. R-hyperCVAD alt. R-HD-MTX

Treatment choices in Mantle Cell Lymphoma

1. Decision making factors:

- Biological age / eligibility for intensive treatment
- Disease associated factors MIPI, Ki67, TP53, CDKN2A
- **2.** Aggressive induction regimens:
 - Nordic protocol
 - R-CHOP+covalent BTKi/R-DHAP
 - (consolidation by ASCT)
 - Maintenance: rituximab + covalent BTKi
 - (Zanubrutinib+venetoclax+obinutuzumab in TP53 mutated)
 - Clinical trial

Treatment choices in Mantle Cell Lymphoma



Addressing CNS involvement

- Rare complication (< 5%) with dismal prognosis (median PFS after CNS directed Th 2.4m)
- HD MTX/AraC
- Intrathecal chemotherapy
- Ibrutinib
- Radiotherapy
- (CAR T-ly)

Figure 1. Overall Survival from CNS diagnosis






Figure 2. Univariable Cox models of OS from CNS diagnosis




¹Stratified covariate Wald p-value; ²Stratified type 3 Wald p-value; ³Covariate Wald p-value;

Case report: treatment response

The patient achieved complete metabolic remission with MRD positivity in BM after R-maxiCHOP/R-DHAP + triple i.t. chemotherapy (ibrutinib was not available at the time (2017))





Q5) What would be nowadays the preferred subsequent treatment after the induction, if any?

- 1. none
- 2. Rituximab maintenance
- 3. +/- ASCT followed by rituximab + ibrutinib maintenance
- 4. ASCT, no maintenance
- 5. Mercaptopurin maintenance


Q5) What would be nowadays the preferred subsequent treatment after the induction, if any?

- 1. none
- 2. Rituximab maintenance

3. +/- ASCT followed by rituximab + ibrutinib maintenance

- 4. ASCT, no maintenance
- 5. Mercaptopurin maintenance

Case report: early progressing disease



The patient fulminantly progressed - before ASCT

- multiple subcutaneous and intramuscular lesions
- Liver, spleen and kidney infiltration
- Bone marrow involvement
- No prove of CNS relapse

Q6) What is the preferred next line treatment option after an early relapse after BTKi containing regimen

- 1. Rituximab-lenalidomide
- 2. Polatuzumab-vedotin+bendamustin+rituximab
- 3. CAR T-cell Therapy
- 4. Idelalisib
- 5. Epcoritamab

Q6) What is the preferred next line treatment option after an early relapse after BTKi containing regimen

- 1. Rituximab-lenalidomide
- 2. Polatuzumab-vedotin+bendamustin+rituximab



- 4. Idelalisib
- 5. Epcoritamab


Relapse after BTKi treatment

Brexu-cel in R/R MCL after BTKi failure


- incl. 17% of pts with confirmed TP53 mut
- ORR 91%, CR 68%
- PFS 26m, OS 47m

	ZUMA-2	SCHOLAR-2
No. patients	68	60
Mean age	63.2 ± 7.8 years	69.5 ± 9.5 years
Median lines th	3 (range, 1-5)	3 (range, 1-6)
After ASCT	43%	37%
Median OS	46.6 months	15.4 months
	HR 0.43 (95% Cl, 0.26-0.68, p < 0.001)	

Figure 2. Combined Overall Survival in ZUMA-2 and ZUMA-18



Patients at risk
 91
 88
 82
 76
 73
 71
 64
 63
 55
 50
 45
 43
 41
 13
 35
 34
 26
 18
 18
 14
 13
 13
 13
 12
 12
 4
 1
 10
 12
 12
 14
 10
 13
 35
 34
 26
 18
 14
 13
 13
 13
 12
 12
 4
 1
 10
 13
 13
 13
 12
 12
 4
 1
 10
 13
 13
 13
 12
 12
 4
 1
 10
 13
 13
 13
 12
 12
 4
 1
 10
 13
 13
 13
 13
 13
 13
 13
 13
 13
 13
 13
 13
 13
 13
 14
 14
 14
 14
 14
 14
 14
 14
 14
 14
 14
 14
 14
 14
 14
 14
 <th




Relapse after BTKi treatment

Brexu-cel in R/R MCL after BTKi failure


- incl. 17% of pts with confirmed TP53 mut
- ORR 91%, CR 68%
- PFS 26m, OS 47m

	ZUMA-2	SCHOLAR-2
No. patients	68	60
Mean age	63.2 ± 7.8 years	69.5 ± 9.5 years
Median lines th	3 (range, 1-5)	3 (range, 1-6)
After ASCT	43%	37%
Median OS	46.6 months	15.4 months
	HR 0.43 (95% Cl, 0.26-0.68, p < 0.001)	

Figure 2. Combined Overall Survival in ZUMA-2 and ZUMA-18



Patients at risk
 91
 88
 82
 76
 73
 71
 64
 63
 55
 50
 45
 43
 41
 13
 35
 34
 26
 18
 18
 14
 13
 13
 13
 12
 12
 4
 1
 10
 12
 12
 14
 10
 13
 35
 34
 26
 18
 14
 13
 13
 13
 12
 12
 4
 1
 10
 13
 13
 13
 12
 12
 4
 1
 10
 13
 13
 13
 12
 12
 4
 1
 10
 13
 13
 13
 12
 12
 4
 1
 10
 13
 13
 13
 13
 13
 13
 13
 13
 13
 13
 13
 13
 13
 13
 14
 14
 14
 14
 14
 14
 14
 14
 14
 14
 14
 14
 14
 14
 14
 14
 <th



Discussion

- Mantle cell lymphoma is an aggressive B-NHL with variable course and prognosis depending on different factors including
 - Tumor volume
 - Proliferation index
 - Cytogenetic/mutation profile
- R-CHOP is usually not suficient to control the disease more intensive regimens incl. HD AraC are needed
- Upfront ASCT should be discussed for eligible patients
- Considering the proven benefit, BTKi should optimally be included in the 1st line treatment and maintenace therapy, particularly for high risk patients

Thank you for your attention









EHA-GBMTA-AHA Hematology Tutorial - New aspects in diagnostic choices and treatment options of hematological malignancies

Self-assessment case 2 Speaker: Kamila Polgárová, Prague, Czech Republic


Tbilisi, Georgia October 18-20, 2024



Introduction

- male, 22 years with no significant history of severe diseases/comorbidities
- Presented with rapidly progressing shortness of breath and cough during SARS-CoV-2 pandemic
- Examination: swelling of the head, neck and partially upper limbs; absent breathing sounds on the left side
- Vital signs at first presentation at the emergency department:
 - BP 115/70mmHg; P 135/min (sinus tachycardia on ECG); satO2 spont. 89%; Temp 37.1°C
- LAB tests: WBC 11x10⁹/L, Hb 124g/L, Plt 480x10⁹/L, ANC 7.2x10⁹/L; CRP 145mg/L; lactate 3.8mmol/L; LDH nor PCT were not tested at the time of admission
- COVID-19 PCR testing was negative

Imaging studies



- X-ray showed massive left-side fluidothorax and mediastinal mass
- Bed-side chest ultrasound confirmed massive pleural effusion
 - A drain was placed 2.5L of fluidothorax was evacuated with characteristics of exsudate
- Bed-side ECHO showed pericardial effusion and D-shaped left ventricle

Q1) What would be the next diagnostic/therapeutic step after stabilizing the patient?

- 1. PET/CT scan
- 2. Cytology of the fluidothorax
- 3. Fine needle biopsy
- 4. Bioptic verification
- 5. Antibiotics and observation
- 6. Pretreatment by cyclofosfamide

Q1) What would be the next diagnostic/therapeutic step after stabilizing the patient?

- 1. PET/CT scan
- 2. Cytology of the fluidothorax
- 3. Fine needle biopsy




- 5. Antibiotics and observation
- 6. Pretreatment by cyclofosfamide

Case report

- The patient underwent transparietal CT navigated biopsy
 - Right after the procedure, corticosteroids were started
- Flow cytometry and cytology of the pleural effusion were performed at the same time
 - Came out negative for pathologic/clonal population

Q2) What is the diagnosis?



Ondrejka SL, Ott G. American Journal of Clinical Pathology. 2021

Q2) What is the diagnosis?

- 1. Classic Hodgkin lymphoma
- 2. Gray zone lymphoma
- 3. Anaplastic large cell lymphoma
- 4. Primary mediastinal B-cell lymphoma
- 5. Burkitt's lymphoma

Q2) What is the diagnosis?

- 1. Classic Hodgkin lymphoma
- 2. Gray zone lymphoma
- 3. Anaplastic large cell lymphoma

4. Primary mediastinal B-cell lymphoma

5. Burkitt's lymphoma

Primary mediastinal B-cell lymphoma

 Specific large B-cell neoplasm with unique clinical and biological properties

 Affects mainly young adults

 Generaly better prognosis comparing to other DLBCL subtypes

Localization/Growth

PMBLAnterior-superiormediastinal mass in thymicarea, occasionally otherextranodal sites orlocoregional lymph nodes

CHL Mediastinal involvement occurs in approximately 78% of cases, involves lymph nodes with contiguous spread

MGZL Most patients have mediastinal involvement (approximately 73%); can include systemic disease

Histology

Diffuse growth of medium- to large-sized cells, with pale to clear cytoplasm and compartmentalizing alveolar sclerosis, occasional pleomorphic cells

Nodules of inflammatory cells and HRS cells separated by broad collagen bands

Sheet-like growth of pleomorphic tumor cells; can be CHL like or PMBL/DLBCL like; paucity of inflammatory cells

Immunophenotype

Strong B-cell antigen expression (CD20, CD79a, CD22, PAX5, BOB1, OCT2, PU.1, CD30 weak/partial, CD23, CD200, cREL, TRAF, MAL

CD30, PAX5 (weak), CD15, sometimes EBV positive, CD20 is typically negative or weak, OCT2 and BOB1 are variable/weak

Divergent from morphology: CHLlike patterns have strong CD20 and B-cell markers, weak/absent CD30, variable CD15; PMBL-like patterns have CD30 and inconsistent or negative CD20 and CD79a and other B-cell markers

Q3) What would be the first line treatment?

- 1. 4x R-CHOP
- 2. R-CHOP / R-AraC
- 3. R-CHOEP or R-DA-EPOCH
- 4. Pola-R-CHP
- 5. GMALL protocol


Q3) What would be the first line treatment?

- 1. 4x R-CHOP
- 2. R-CHOP / R-AraC
- 3. R-CHOEP or R-DA-EPOCH
 - 4. Pola-R-CHP
 - 5. GMALL protocol

Treatment options

- 6x R-CHOP21
- 4-6x R-CHOP14
- 6x R-DA-EPOCH
- 6x R-CHOEP14/21
- +/radiotherapy

NCCN guidelines 2024 Wasterlid T et al. Blood Cancer J 2021 Vassilakopoulos T et al. Oncologist 2012 Dunleavy K et al. NEJM 2013



Q4) How would you asses the treatment response

- 1. PET/CT scan during (after 2-3 cycles) and after (6 cycles) the chemoimmunotherapy
- 2. PET/CT scan after finishing the 6 cycles of chemoimmunotherapy
- 3. CT scan during (after 2-3 cycles) and after(6 cycles) the chemoimmunotherapy
- 4. CT scan after finishing the 6 cycles of chemoimmunotherapy
- 5. X-ray during the treatment and PET/CT scan after finishing chemoimmunotherapy

Q4) How would you asses the treatment response

1. PET/CT scan during (after 2-3 cycles) and after (6 cycles) the chemoimmunotherapy


- 2. PET/CT scan after finishing the 6 cycles of chemoimmunotherapy
- 3. CT scan during (after 2-3 cycles) and after(6 cycles) the chemoimmunotherapy
- 4. CT scan after finishing the 6 cycles of chemoimmunotherapy
- 5. X-ray during the treatment and PET/CT scan after finishing chemoimmunotherapy

Evaluating response during and after therapy

For **FDG avid** neoplasms:

- PET/CT at time of dg to asses the extent of the disease
- PET/CT interim (after 2-3 treatment cycles) + final (after finishing the therapy) to asses response of the disease
- Response criteria:
 - Lugano criteria Deauville five-point scale
 - LYRIC criteria (for immunomodulatory drugs)

Case report – residual mass with Deauville PS3



Q5) What, if any, would be the proper consolidation?

- 1. Rituximab maintenance
- 2. Brentuximab vedotin maintenance
- 3. Radiotherapy
- 4. ASCT
- 5. None


Q5) What, if any, would be the proper consolidation?

- 1. Rituximab maintenance
- 2. Brentuximab vedotin maintenance
- 3. Radiotherapy
- 4. ASCT



Role of radiotherapy after achieving CR

R-DA-EPOCH (no RT)



IELSG37: Kaplan-Meier estimate of progression-free survival 1.00 -P= 0.274 Observation Radiotherapy Months from randomisation Number at risk ng q۷

Dunleavy K et al. NEJM 2013 Martelli M et al. Hemasphere 2023. Suppl

Q6) What would be your treatment suggestion in case of progression/relapse?

- 1. Loncastuximab-tesirin
- 2. Ibrutinib+venetoclax
- 3. Salvage platinum regimen + ASCT
- 4. Tisagenlecleucel
- 5. Single agent nivolumab

Q6) What would be your treatment suggestion in case of progression/relapse?

- 1. Loncastuximab-tesirin
- 2. Ibrutinib+venetoclax


3. Salvage platinum regimen + ASCT

- 4. Tisagenlecleucel
- 5. Single agent nivolumab

Treatment options in relapsed / refractory disease


- Salvage platinum + ASCT
- Pembrolizumab (KEYNOTE-170)
 - R/R disease with relapse after ASCT or not eligible for ASCT
- Nivolumab+brentuximab-vedotin (CheckMate 436)
 - R/R disease with relapse after ASCT or not eligible for ASCT after ≥2 therapeutic lines
- CAR T-ly:
 - axicabtagene ciloleucel (3rd + line)
 - lisocabtagene maraleucel (2nd line in early relapse or 3rd + line)

Aoki T et al. Blood Cancer J 2015 Neelapu SS et al. NEJM 2017 Zinzani PL et al. Blood Adv 2023 Zinzani PL et al. Blood 2023 Abramson LS et al. Lancet 2020 Kamdar M et al. Lancet 2022



CheckMate 436





Discussion

- PMBL is specific type of B-NHL affecting mostly young adults
- The therapy is based on rituximab + anthracyclin regimen, mostly CHOP or DA-EPOCH
- Radiotherapy consolidation can mostly be ommited in patients achieving metabolic complete remission (DS 1-3 on final PET/CT scan)
- Treatment options in relapsed settings include check-point inhibitors, brentuximab vedotin, CAR T-cell therapy or salvage chemoimmunotherapy with ASCT

Thank you for your attention





